Protalix BioTherapeutics (PLX) EPS (Weighted Average and Diluted) (2011 - 2026)
Protalix BioTherapeutics (PLX) recorded quarterly EPS (Weighted Average and Diluted) of $0.22 in Q1 2026, up 414.29% quarter-over-quarter from -$0.07 in Q4 2025, and up 540.0% on a YoY basis from $0.03 in Q1 2025.
Protalix BioTherapeutics (PLX) EPS (Weighted Average and Diluted) (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' EPS (Weighted Average and Diluted) history runs 14 years deep, the most recent figure standing at $0.22 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 540.0% year-over-year to $0.22; the TTM figure through Mar 2026 stood at $0.18 (up 350.0% YoY), while the FY2025 annual figure was -$0.08, down 300.0% from the prior year.
- EPS (Weighted Average and Diluted) was $0.22 for Q1 2026 at Protalix BioTherapeutics, up from -$0.07 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.22 in Q1 2026 to a low of -$0.11 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.01 across 5 years, with a median of -$0.05 in 2022.
- The sharpest annual moves came in 2025 and 2026: EPS (Weighted Average and Diluted) sank 177.78% in 2025, then soared 540.0% in 2026.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.07 in 2022, then changed by 0.0% to -$0.07 in 2023, then soared by 228.57% to $0.09 in 2024, then sank by 177.78% to -$0.07 in 2025, then surged by 414.29% to $0.22 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.22 (Q1 2026), -$0.07 (Q4 2025), and $0.03 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Protalix BioTherapeutics | 176.47 Mn | 165.67 Mn | 29.62 Mn | 0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.22 |
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | 0.03 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | 0.09 |
| Sep 30, 2024 | 0.03 |
| Jun 30, 2024 | -0.03 |
| Mar 31, 2024 | -0.06 |
| Dec 31, 2023 | -0.07 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | 0.21 |
| Mar 31, 2023 | -0.05 |
| Dec 31, 2022 | -0.07 |
| Sep 30, 2022 | -0.07 |
| Jun 30, 2022 | -0.11 |
| Mar 31, 2022 | -0.05 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.25 |
| Mar 31, 2021 | -0.14 |